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1.1. Background
Owing to aging populations, incidence of dementia is
estimated to triple by 2050, representing the greatest chal-
lenge for health care in the 21st century [1]. In addition to
affecting the individual living with dementia, there are
considerable consequences for wider society given the asso-
ciated emotional, health, and social care costs. Effective ap-
proaches to treating the underlying illnesses that cause
dementia are still largely absent, thus emphasizing the
need for prevention.
Most neuropathological processes start years before the
onset of dementia [2,3]; hence, there is a growing need to
target modifiable risk factors in individuals in the earliest
stages for intervention when neurodegeneration is still
limited [4]. In support of advancing preventative strategies,
research shows that approximately a third of dementia cases
worldwide might be attributable to potentially modifiable
risk factors [5]. Indeed, the risk of dementia increases
when adverse factors, including anxiety, depression, stress,
and sleep disturbances, are present. Sleep disorders are
known to promote dementia-related pathological processes
[6], and in older adults, each depressive symptom increases
dementia risk by approximately 20% [7]. Importantly, longi-
tudinal studies show that anxiety increases the rate of cogni-
tive decline in individuals at risk of dementia [8], and a
recent meta-analysis implicated late-life levels of anxiety
symptoms as a predictor of dementia [9]. Increasing evi-
dence supports that subjectively experienced cognitive
decline, even when performance on cognitive tests is in the
normal range, is also associated with an increased risk for
future cognitive decline and dementia [10,11]. A high
level of anxiety is a characteristic feature of patients living
with subjective cognitive decline (SCD) [12], which may
further exacerbate risk for dementia and reduced well-being.
1.2. Mindfulness-based intervention
Although mindfulness-based research in older adults is
still in its infancy, there is considerable evidence that theseinterventions can reduce anxiety in a number of populations,
including preliminary studies in older adults [13,14].
Mindfulness-based interventions (MBIs), derived from the
generic mindfulness-based stress reduction program devel-
oped by Dr. Jon Kabat-Zinn [15], combine intensive training
in mindfulness meditation with psychoeducational compo-
nents and provide individuals with sustainable skills that
remain at their disposal beyond the intervention period.
MBIs use a secular form of meditation training that empha-
sizes focused, nonjudgmental awareness of present moment
experiences. Participants typically meet for weekly group-
based sessions for 8 weeks and engage in home practices be-
tween sessions.
In addition to reducing anxiety, promising evidence
also shows that MBIs improve cognitive function in areas
most sensitive to aging and dementia (such as attention
and memory) [16,17]. Further research shows that these
interventions can reduce stress, depression, insomnia,
feelings of loneliness, and social exclusion [14,18,19], as
well as cardiovascular risk factors [20]—all of which are
associated with increased risk for dementia [21,22].
Indeed, recent evidence suggests that an MBI altered
levels of a blood-based biological marker associated
with both stress and dementia in at-risk older adults [23].
Importantly, mindfulness-based training is a scalable,
community-based, and low-cost intervention that is broadly
available.
1.3. Choice of comparator
Many of the previous studies of MBIs have suffered from
a lack of an adequate comparison condition and lack of
follow-up to know whether initial benefits are maintained.
As MBIs contain a number of nonspecific elements, such
as social interaction, light exercise, or the provision of treat-
ment expectancies, the use of active control or comparison
interventions is important. Based on the assumption that
training in mindfulness is the crucial active component of
the intervention and to control for effects due to other as-
pects of the program, we selected a health education pro-
gram as the comparison condition. The health education
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training in overall course length, class time and home activ-
ities, and matched to the training in administration, dosage,
and duration. It is a facilitator-led, group-based program,
based on a published book [24], and developed and validated
in an SCD population by colleagues in the United States
[25]. The program was designed to equalize treatment ex-
pectancy across conditions, parallel psychoeducational com-
ponents, and to control for the nonspecific effects of
increased social interaction and light physical activity.
Moreover, the health education programmay have a positive
impact on well-being in the SCD population by fostering
self-efficacy. Participants with SCD and comorbid clinical
anxiety and/or depression in the trial by Wetherell et al.
believed this program was a credible intervention and
showed nonsignificant improvements in memory, as ex-
pected in a comparison condition [25]. However, partici-
pants in this condition did not show significant
improvement in anxiety symptoms compared with those in
the mindfulness-based condition [26].
1.4. Trial objectives and purpose
The SCD-Well trial is part of the “Medit-Ageing” proj-
ect (public name: Silver Sante Study; www.
silversantestudy.eu) funded through the European Union
as part of the Horizon 2020 program. SCD-Well will use
an MBI that is specifically tailored to the needs of older
adults building on modifications suggested by Zellner Kel-
ler et al. [27] together with a particular focus on compas-
sion and loving kindness practices. This upgrade takes
into account emerging clinical evidence showing a comple-
mentary and beneficial role of this style of meditation on
anxiety and depression [27–30].
The primary objective of the trial is to test whether an 8-
week MBI is superior to an 8-week health education pro-
gram on reducing anxiety in older adults with SCD in a
multicenter randomized controlled trial. We will further
examine whether any changes in anxiety symptoms are
maintained 4 months after the end of the intervention, and
whether the intervention affects a series of outcomes
including mental health and cognitive functions, social rela-
tions, and biological markers.2. Methods/design
2.1. Trial design and setting
SCD-Well is a European multicenter, observer-blind, ran-
domized, controlled, superiority trial with two parallel
groups: an MBI or a validated health-educational program.
The trial includes 8 weeks of intervention and 16 weeks of
follow-up (total of 24 weeks) and is designed to compare
outcomes from the two intervention groups. The interven-
tion takes place in group settings at four sites, and random-
ization is performed with a 1:1 allocation, stratified by study
site. The study schedule is summarized in Table 1, anddetailed descriptions of participant visits are provided in
Supplementary Material 1. Briefly, participants are recruited
from medical facilities, prescreened, and then invited to a
screening visit (V0) where the diagnostic battery is per-
formed (Table 2) and eligibility is assessed. Participants ful-
filling eligibility criteria (Table 3) are invited to the baseline
visit (V1) and then randomized to one of the two interven-
tion groups. Allocation and assignment of interventions
are described in Supplementary Material 1. A postinterven-
tion visit (V2) is conducted after the end of the intervention,
and a follow-up visit (V3) is held 4 months after the end of
the intervention. The primary outcome is change in
symptoms of anxiety from V1 to V2. For secondary out-
comes, treatment effects are assessed as change from V1
to V2 or V3.
Participants are recruited from medical facilities (e.g.,
memory clinics) at the four centers where the trial assess-
ments and delivery of the interventions take place (London,
UK; Cologne, Germany; Lyon, France; Barcelona, Spain).
More detail about the sites is provided in Supplementary
Material 1. Participants are patients who are either referred
to a memory clinic by a physician or who are self-referrals.
2.2. Data collection
Validated behavioral measures chosen for their sensitivity
to aging and early dementia and/or meditation were selected
for the trial (see Supplementary Table 1 for details). Briefly,
behavioral measures include neuropsychological tests that
assess different cognitive functions (e.g., episodic memory,
attention, executive function) and questionnaires that
include assessments of personality traits; sleep quality; life-
time and current engagement in cognitive, social, and phys-
ical activities; Mediterranean diet adherence; health-related
behaviors such as self-medication, smoking and alcohol con-
sumption; quality of life and well-being; and mental health
indicators such as anxiety and depression and loneliness.
Some questionnaires are also given to a participant’s close
relative or friend (subsequently referred to as the “partner”).
Behavioral measures and blood sampling are conducted at
V1, V2, and/or V3. Details regarding the collection of blood
specimens can be found in Supplementary Material 2.
To standardize the administration and scoring of neuro-
psychological tests and questionnaires, psychometrists
from all sites completed a standardized administration and
scoring training that was developed specifically for the
study.
2.3. Interventions
The MBI uses meditation and yoga practices adapted for
older adults [27] and, in line with the standard format of
mindfulness-based stress reduction, consists of a pre-class
meeting with the facilitator in which the participants are
socialized to the treatment, eight weekly group-based ses-
sions of 2 to 2½ hours duration, a half-day of meditation
practice after the sixth session of the program (9 sessions
Table 1
Study schedule
Schedule of events
Screening
Baseline
assessment
and
randomization
Intervention
period
(8 weeks)
Postintervention
assessment
4-month
follow-up
assessment
V0 V1 V2 V3
Enrollment
Eligibility screen X X
Oral and written information X
Signed informed consent X
Randomization X
Assessments
Baseline characteristics X
Primary outcome
State-Trait Anxiety Inventory (STAI) X X X
Secondary and exploratory outcomes (see Supplementary Table 1
for detailed measures)
Medical background X X X
Global cognition X X X
Thinking and reasoning X
Attention/executive function X X X
Memory X X X
Language X X X
Psychoaffective/emotion X X X
Compassion, support, mindfulness X X X
Sleep X X X
Personality X
Lifestyle X X X
Quality of life and well-being X X X
Biological measures X X X
Partner questionnaires X X X
Intervention
Mindfulness-based intervention
Health education program
Completion of workbook/questionnaires to monitor intervention
adherence and response
X indicates that the event occurred during that time in the study schedule. The symbol in question indicates that the intervention period was ongoing for 8
weeks.
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intensive training in mindfulness and compassion medita-
tion and gentle yoga practices with psychoeducationalTable 2
Diagnostic battery
Domains evaluated Tests
Global cognitive
functioning
Cognitive assessment according to site-specific
memory clinical standards to diagnose SCD (if
needed)
MMSE [31]
Depression and
anxiety
Standardized questions to assess generalized anxiety
and major depression (DSM-5 [32]/ICD-10
checklist [33][p10])
SCD criteria Meets research criteria for SCD [11]
Memory concern Expressed concern about memory (either by visiting
a memory clinic or assessed via a question at
screening)
Abbreviations: DSM-5, Diagnostic and Statistical Manual of Mental Dis-
orders, fifth edition; ICD-10, International Statistical Classification of Dis-
eases and Related Health Problems, 10th revision; MMSE, Mini–Mental
State Examination; SCD, subjective cognitive decline.components targeted at helping individuals to deal more
effectively with emotional difficulties and stressors
commonly encountered in older age, particularly stressors
related to concerns about cognitive functioning and health.
The program has a particular emphasis on cultivating
wholesome attitudes toward oneself and others. Meditation
and yoga practices focus on strengthening attentional ca-
pacities and bodily awareness during the first half of the
program. Practices in the second half of the program build
on these skills to establish more effective ways of respond-
ing to difficult experiences. Participants are asked to
engage in home practice for approximately an hour per
day, 6 days per week. Home practice consists of formal
meditation practices guided by meditation recordings and
informal practices aimed at helping participants to gener-
alize mindfulness skills to their daily life. Participants
receive a workbook that explains the home practices and
that is used to record adherence to them.
The health education control intervention follows the
same format and structure as the MBI and is matched to
Table 3
Eligibility criteria
Inclusion criteria Exclusion criteria
 Aged 60 years.
 Meets research criteria proposed by the SCD-I working group [11].
 Performance within the normal range on standardized cognitive tests
already administered at each site as part of standard clinical assess-
ments according to research criteria based on those defined by Jak and
Bondi [34,35] for exclusion of MCI as recommended by Molinuevo
et al. [36].
 Participants are excluded if they score below the normative range
on two tests within a single cognitive domain (i.e., memory, ex-
ecutive function, language) or if they score below the normative
range on one test within each cognitive domain.
 Results from prespecified tests in memory, executive function, and
language from the baseline cognitive assessment are examined as
an additional check to ensure comparable cognitive performance
across sites using the same measures and criteria.
 Being referred to the memory clinic by a physician or self-referral
because of memory concerns.
 Ability to provide informed consent in accordance with International
Conference on Harmonization of Good Clinical Practice (GCP/ICH)
guidelines and local regulations.
 Stating that they are available for the trial duration (39 weeks).
 Presence of a major neurological or psychiatric disorder (including
anxiety disorders, major depressive disorder, or an addiction to
alcohol or drugs) according to the International Statistical Classifi-
cation of Diseases and Related Health Problems, 10th revision [33]
and/or Diagnostic and Statistical Manual of Mental Disorders, fifth
edition [32] criteria.
 Under legal guardianship or incapacitation.
 History of cerebral disease (vascular, degenerative, physical malfor-
mation, tumor, or head trauma with loss of consciousness for more
than an hour), which interferes with the aims of the study protocol.
 Visual or auditory impairment sufficient to interfere with the aims of
the study protocol.
 Presence of a chronic disease or acute unstable illness (respiratory,
cardiovascular, digestive, renal, metabolic, hematologic, endocrine,
or infectious), which interferes with the aims of the study protocol.
 Current or recent medication that may interfere with cognitive action
(psychotropic, systemic corticosteroid, anti-Parkinson’s, or analgesic
drugs). The interfering nature of the different treatments is at the
discretion of the investigating doctor.
 Regular or intensive practice of meditation or comparable practices
(yoga, Qigong, Alexander technique), that is, more than 1 day per
week for more than 6 months consecutively over the last 10 years,
intensive practice (internship or retreat. five consecutive days) over
the past 10 years, or more than 25 days of retreats (cumulatively)
before the last 10 years.
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cifically, it consists of a pre-class meeting with the facili-
tator, eight weekly group-based sessions of 2 to 2½ hours
duration, a half-day of practice after the sixth session of
the program (9 sessions in total), and home practices. The
treatment is based on a published manual [24], with every
session of the program covering different subjects, including
self-management; problem-solving; sleep; stress; exercise;
managing medicines and memory; communicating with
family, friends, and health care professionals; eating; weight
management; and planning for the future. Participants are
provided with information about these subjects and engage
in group exercises and discussions about them. They are
given a workbook and asked to actively engage in activities
described in the workbook to improve health and well-being
on 6 days each week, matching home assignments in the
MBI. The workbook summarizes the most important points
of each session, and participants are asked to record engage-
ment in health-related activities on protocol sheets in the
workbook.
Each site has two facilitators, each with a psychology/
psychotherapy degree and/or significant experience in
leading group-based therapies. One facilitator, who has
undergone formal training to match criteria of the good
practice guidelines of the UK network of mindfulness-
based teacher trainers, delivers the MBI. The other
facilitator who has at least 3 years’ experience leading
group-based clinical programs and/or psychoeducational
interventions (e.g., a clinical psychologist or equivalent)leads the health education intervention. Both sets of facil-
itators received the intervention protocol, instruction, and
a day-long training about their respective intervention
before the start of the study to promote standardization
of the intervention delivery across sites. To document
manual adherence, facilitators of both interventions
complete self-report checklists after each class. Facilita-
tors are supervised in weekly individual sessions by the
intervention leads. The two interventions are delivered
to groups of approximately 10 participants and take
place in a designated room at the memory clinic or
investigator-affiliated facility.
After the first session of the intervention, participants of
both intervention groups complete a questionnaire to record
their expectations for the credibility and efficacy of their
intervention [37]. They also report levels of depression
over the past week at the beginning of each intervention ses-
sion. Participants are also encouraged to record any impor-
tant comments they might have about the practice to
provide qualitative information. Adherence (i.e., class atten-
dance) is collected by facilitators. Participants who choose
to drop out of the intervention are invited to continue taking
part in assessments.2.4. Outcomes
Given its prevalence in SCD and relation to objective
cognitive decline and dementia risk, the primary outcome
is the mean change in anxiety from V1 to V2, in each group.
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of the State-Trait Anxiety Inventory (STAI) [38]. We had
initially intended to use the state version of the STAI as a pri-
mary outcome but took the decision to use the trait version
for two reasons—(1) the state version assesses transient anx-
iety symptoms that are more susceptible to situational vari-
ation and (2) intermediate reports indicated floor effects of
baseline data for the state, but not the trait-STAI, potentially
due to entry to treatment in the trial. Trait-STAI scores are
more representative of a person’s general level of anxiety
and less dependent on situational factors, which may not
be fully standardized across sites. Previous research has
shown that increased trait anxiety is a characteristic of
SCD samples [39]. The change in primary outcome measure
from state-STAI to trait-STAI was approved by the Trial
Steering Committee, before any statistical analyses.
Although trait-STAI will be the primary outcome of this
trial, the effects of the interventions on state-STAI will be as-
sessed as a secondary outcome. Other secondary outcomes
include
 mean change in anxiety (measured by the trait-STAI)
from V1 to V3,
 mean change in behavioral measures (see
Supplementary Table 1 for specific outcomes)
observed (a) from V1 to V2 and (b) from V1 to V3,
 mean change in blood-based markers of stress and de-
mentia risk observed (a) from V1 to V2 and (b) from
V1 to V3,
 change in mean numbers of visits to general practi-
tioners/medical doctors and the medication use during
and after the intervention, and
 mean changes in measures of emotions/psychoaffec-
tive functioning, compassion, support, and mindful-
ness assessed by partners of participants.
Moderator analyses will establish whether factors
including sex, personality characteristics, genetic pheno-
types, general thinking and reasoning skills, and life experi-
ences and diet affect the outcomes of the intervention. Study
data will also be used for exploratory analyses unrelated to
the intervention.2.5. Statistical considerations2.5.1. Sample size
As the STAI anxiety score has no absolute cutoff
levels, sample size consideration is based on effect size
(i.e., the ratio between the expected interarm differences
to the common standard deviation). With a minimum ef-
fect size of 0.50 (indicated as a reasonable expectation
from a meta-analysis summarizing the efficacy of medita-
tive therapies for reducing anxiety) [13], 64 participants
per arm need to be included to demonstrate a significant
difference in the primary endpoint (mean difference in
the change of the trait-STAI score in each trial arm be-tween baseline and the end of the intervention) in a
t-test with 80% power and a two-sided type I error of
5%. As the minimum relevant effect size was considered
to be the same for the state- and trait-STAI, sample size
remained unchanged after the change of the primary
endpoint.
2.5.2. Statistical methods
The planned statistical analyses are described in a trial
statistical analysis plan and summarized in Supplementary
Material 1. Briefly, the primary outcome analyses will be
conducted on an intent-to-treat principle, and missing pri-
mary endpoint data will be handled with a conservative a
“missing5 failure” strategy. Additional analyses conducted
on both primary and secondary outcomes will include sensi-
tivity analyses, undertreatment and per protocol analyses,
and analyses of exposure/dose effects. For exploratory non-
comparative analyses, complete case analyses or imputation
methods will be considered on a case-by-case basis, depend-
ing on the amount of missing data and the specific research
question.
2.6. Ethics, safety, and study monitoring
The SCD-Well trial was approved by the necessary
ethics committees and regulatory agencies in London,
UK (Queen Square Research Ethics Committee and
Health Research Authority); Lyon, France (Comite de
Protection des Personnes CPP Sud-Est II Groupement
Hospitalier and Agence Nationale de Securite du
Medicament et des Produits de Sante); Cologne, Germany
(Ethikkommission der Medizinischen Fakult€at der Uni-
versit€at zu K€oln); and Barcelona, Spain (Comite Etico
de Investigacion Clinica del Hospital Clinic de Barce-
lona), registered on ClinicalTrials.gov (Identifier:
NCT03005652), and adheres to Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT)
guidelines for clinical trial protocols [40] (see
Supplementary Material 1 for further details and
Supplementary Table 2 for SPIRIT checklist).
The sponsor established a Trial Steering Committee
according to Good Clinical Practice guidelines with the
responsibility to provide oversight on the conduct of
the trial, advise on scientific credibility on behalf of the
sponsor and the funder, and assess the progress of the
protocol. More details on data management, monitoring,
dissemination and access, and study governance (blinding,
safety, auditing) are contained in the Supplementary
Material 1.
3. Discussion
The primary aim of the SCD-Well study is to establish
whether an 8-week MBI as compared to 8-week health edu-
cation training can reduce anxiety levels in older adults with
SCD. This will be assessed through the use of a multicenter
randomized superiority trial. As anxiety symptoms are not
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also represent a risk factor for dementia [8,21,42], this
study aims to provide an initial step toward testing the
potential of mindfulness-based training as a new form of
intervention to improve well-being and prevent cognitive
decline and ultimately delay the onset of dementia. Further-
more, the study is aimed at providing rigorous evidence
regarding the immediate and sustained effects of mindful-
ness training on a range of other psychological and biolog-
ical factors that are indicators of health, well-being, and
cognitive functions.
3.1. Practical issues
The SCD-Well trial is conducted in several countries
with the aim of establishing whether an MBI is broadly
applicable for older persons with SCD. However, if there
are strong cultural differences in the response to the
training, this could increase the heterogeneity across sites
in the overall expected effect. Analyses of responder char-
acteristics could help to address such biases in future
studies. We have excluded participants with anxiety levels
reaching clinical significance to limit potential confound-
ing from psychiatric illness, but we have not set a lower
limit for anxiety levels as it is well documented that anxi-
ety is a common symptom in people with SCD. This crite-
rion does however create the possibility that we may not
detect an effect of the intervention because of participants’
low levels of baseline anxiety symptoms.
Although this study benefits from a 4-month follow-up
assessment to examine whether any changes due to the inter-
vention are maintained, future studies would profit from still
longer-term follow-up assessment(s), which could examine
the duration of possible effects and include monitoring of
conversion to dementia. Finally, we have included an active
comparison condition that will be used to examine whether
mindfulness-based training confers a specific advantage
over another form of behavioral intervention; however, we
did not include a passive control condition due to recruit-
ment and financial constraints. If no difference is found be-
tween the mindfulness-based and comparison interventions,
it will therefore be difficult to show whether this is because
neither or both were effective at reducing anxiety.
3.2. Operational issues
Although great care was taken in the conceptualization
and preparation of the SCD-Well trial, there are some
operational issues that are inherent in the dependent mea-
sures. First, the main endpoint, anxiety, is only assessed
through a questionnaire and is thus not blinded to the allo-
cated intervention. Although the employed questionnaire
has been extensively validated, our endpoint relies on
participants’ capacity to give an accurate report of their
anxiety levels. To complement potential biases through
self-reports in relation to our secondary objectives, partic-
ipants’ partners (for example, spouses, children, neighbors,close friends) are also invited to fill in a set of question-
naires. A second operational issue is encountered by the
fact that we only have few objective risk markers for de-
mentia (e.g., apolipoprotein E [APOE] 34 genotype, hyper-
tension) and that neuroimaging-based dementia markers
(such as b-amyloid levels, hippocampal volume) are not
collected in this study due to feasibility and cost issues.
Those measures will, however, be collected in the AGE-
Well Study, which is also part of the Medit-Ageing project.
Despite minimal collection of biomarkers, we will store
whole blood and plasma samples for future analyses as
novel blood-based biomarkers are found and refined and
will make use of a number of behavioral and psychiatric
risk factors that will be measured in SCD-Well (e.g.,
depressive symptoms, poor sleep).
In summary, the SCD-Well study aims to test whether
mindfulness-based training can be regarded as an alterna-
tive approach to reduce anxiety and maintain mental health
and well-being in older age. If mindfulness-based training
can promote healthy aging in people with SCD, it will offer
a novel and alternative therapeutic and preventive approach
for a population who currently lacks treatment options.Acknowledgments
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1. Systematic review: Older adults with subjective
cognitive decline (SCD) report concerns about self-
perceived cognitive decline but appear normal on
assessment. SCD is associated with increased risk for
dementia and also increased anxiety symptoms.
Database searches for clinical trials indicate that few
nonpharmacologic interventions have been trialed
for patients with SCD, and those that have are often
unicentric, small, have no active control condition,
and/or no longitudinal follow-up.
2. Interpretation: SCD-Well is the first large-scale,
multicountry randomized controlled trial with a
long-term follow-up in older adults with SCD. It
assesses for the first time the effects of an 8-week
mindfulness-based intervention compared to a health
education program on anxiety symptoms and mea-
sures of psychological, cognitive, social, and bio-
logical functioning.
3. Future directions: SCD-Well will provide evidence
on whether a mindfulness-based intervention can
reduce anxiety and other dementia risks. It will
inform future trials and strategies to improve mental
health and prevent cognitive decline in SCD.References
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